Preeclampsia (PE) is a hypertensive disorder in pregnancy associated with significant fetal and maternal complications. Antiphospholipid syndrome (APS) is an acquired form of thrombophilia characterized by recurrent venous or arterial thrombosis and obstetric complications that significantly increases morbidity and mortality rates. While preeclampsia may not be the most prevalent obstetric complication in APS, it significantly impacts the long-term health of both mother and child. The treatment of preeclampsia in antiphospholipid syndrome is different from the treatment of preeclampsia as an independent disease. Despite current treatments involving anticoagulants, antiplatelet agents, and antihypertensive drugs, obstetric complications may persist, underscoring the need for cohesive management and effective treatments. The objective of our review is to briefly present knowledge about the physiopathology of preeclampsia and the role of antiphospholipid antibodies in this process. Based on the existing literature, our review aims to identify future directions in molecular pathology toward the discovery of biomarkers and targeted treatments. The application of multidisciplinary approaches and prognostic models, including new biomarkers, could be beneficial in the prediction of PE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11084819 | PMC |
| http://dx.doi.org/10.3390/jcm13092668 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical implications of human Parvovirus B19 infection on autoimmunity and autoimmune diseases.
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFInhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy.
Mediators Inflamm
January 2025
Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Article Synopsis
- Antiphospholipid antibody syndrome (APS) is an autoimmune disease that causes blood vessel problems and can lead to serious kidney damage known as nephropathy.
- Researchers tested a Tyk2 inhibitor, BMS-986202, on mice with APS nephropathy to assess its effects on the disease.
- The study found that Tyk2 inhibition not only improved kidney function and reversed harmful changes in the kidneys, but also reduced the type I interferon (IFN) signature associated with the disease, indicating a potential new treatment approach for APS nephropathy.
Role of the Systemic Immune-Inflammation Index and Systemic Immune-Response Index in the Prediction of Adverse Outcomes in Pregnant Women With Antiphospholipid Syndrome.
Am J Reprod Immunol
January 2025
Department of Obstetrics and Gynecology, Necmettin Erbakan University Medical School of Meram, Konya, Turkey.
Problem: This study aims to evaluate the role of the systemic immune-inflammation index (SII) and the systemic immune-response index (SIRI) in predicting adverse perinatal outcomes (APO) in pregnant women with antiphospholipid syndrome (APS).
Methods: This is a retrospective case-control study at the tertiary center, between January 2015 and January 2023. The study included APS cases and a low-risk control group.
Interpreting high levels of unfolded Von Willebrand Factor in patients with the antiphospholipid syndrome.
Front Immunol
December 2024
Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.
Introduction: Unfolded Von Willebrand Factor (VWF) is increased in thrombotic pathologies such as myocardial infarction. Unfolded VWF mediates the binding of platelets without the need for collagen. β-glycoprotein I (β-GPI) is a natural inhibitor of the platelet-VWF interaction.
View Article and Find Full Text PDFAssociation between antinuclear antibodies and pregnancy prognosis in recurrent pregnancy loss patients.
Hum Reprod
December 2024
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Study Question: Can antinuclear antibodies (ANA) affect the subsequent live birth rate (LBR) in patients with unexplained recurrent pregnancy loss (RPL) in the absence of antiphospholipid antibodies (aPL)?
Summary Answer: Women with unexplained RPL have a high probability of live birth following a positive pregnancy test (>70%), being similar between those with positive and negative ANA testing, regardless of the cut-off value.
What Is Known Already: The RPL guidelines of the ESHRE state that 'ANA testing can be considered for explanatory purposes'. However, there have been a limited number of studies on this issue and sample sizes have been small, and the impact of ANA on the pregnancy prognosis is unclear.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!